Tuesday, May 26, 2009

Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452

Cytokinetics Receives Exercise Fee of $50 Million; Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET

SOUTH SAN FRANCISCO, Calif. and THOUSAND OAKS, Calif., May 26 /PRNewswire-FirstCall/—Cytokinetics Incorporated (Nasdaq: CYTK) and Amgen Inc. (Nasdaq: AMGN) today announced that Amgen has exercised its option to obtain an exclusive license, worldwide (excluding Japan), to Cytokinetics’ cardiac contractility program. The license includes CK-1827452, a novel cardiac myosin activator being developed for the treatment of heart failure.

Posted in Press Releases